AXSM Logo

Axsome Therapeutics, Inc. (AXSM) 

NASDAQ
Market Cap
$4.22B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
558 of 960
Rank in Industry
304 of 550

Largest Insider Buys in Sector

AXSM Stock Price History Chart

AXSM Stock Performance

About Axsome Therapeutics, Inc.

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation. It is also developing AXS-07, a novel, oral, rapidly …

Insider Activity of Axsome Therapeutics, Inc.

Over the last 12 months, insiders at Axsome Therapeutics, Inc. have bought $0 and sold $9.66M worth of Axsome Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Axsome Therapeutics, Inc. have bought $242,389 and sold $5.94M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,950 shares for transaction amount of $147,350 was made by JEFFS ROGER (director) on 2021‑11‑19.

List of Insider Buy and Sell Transactions, Axsome Therapeutics, Inc.

2024-09-11Saledirector
11,016
0.0226%
$91.31$1.01M+0.48%
2024-08-09SaleChief Operating Officer
47,739
0.1009%
$84.26$4.02M+9.62%
2024-05-29Saledirector
5,248
0.011%
$75.14$394,333+18.40%
2024-05-29SaleChief Operating Officer
7,910
0.0165%
$74.31$587,813+18.40%
2024-05-28Saledirector
5,249
0.0108%
$75.21$394,775+15.82%
2024-04-01SaleChief Operating Officer
24,662
0.0522%
$77.24$1.9M+10.40%
2024-03-15Saledirector
2,347
0.0047%
$71.61$168,062+11.76%
2024-03-14Saledirector
16,976
0.036%
$69.70$1.18M+20.84%
2023-09-15Saledirector
29,588
0.0626%
$75.18$2.22M-0.49%
2021-11-19Purchasedirector
3,950
0.0109%
$37.30$147,350+3.44%
2021-11-18Purchasedirector
1,430
0.0037%
$35.09$50,181+4.03%
2021-11-18PurchaseCHIEF FINANCIAL OFFICER
955
0.0025%
$35.26$33,676+4.03%
2021-11-17Purchasedirector
3,300
0.0087%
$34.52$113,922+7.00%
2021-05-12Purchasedirector
500
0.0014%
$58.15$29,075-38.38%
2020-06-29Purchasedirector
650
0.0018%
$78.50$51,025-5.10%
2020-06-29PurchaseChief Financial Officer
777
0.0021%
$76.64$59,549-5.10%
2019-09-26PurchaseChief Financial Officer
2,180
0.0063%
$24.80$54,064+210.19%
2019-06-26Purchasedirector
15,800
0.0481%
$23.10$364,980+145.30%
2019-06-25Purchasedirector
400
0.0011%
$23.25$9,300+126.86%
2019-06-11PurchaseChief Financial Officer
1,920
0.0057%
$20.80$39,936+117.89%

Insider Historical Profitability

49.9%
JEFFS ROGERdirector
120756
0.2492%
$87.1612+3.44%
Coleman Markdirector
14600
0.0301%
$87.1673+51.01%
Saad Mark Edirector
10002
0.0206%
$87.1621+23.86%
Pizzie NickCHIEF FINANCIAL OFFICER
41789
0.0862%
$87.1660+75.66%
Kaye RandallChief Medical Officer
6022
0.0124%
$87.1610<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
RTW Investments, LP$358.52M9.464.49M+0.07%+$246,023.405.37
The Vanguard Group$298.47M7.883.74M+1.18%+$3.47M0.01
BlackRock$255M6.733.2M-1.37%-$3.53M0.01
Fairmount Funds Management LLC$188.33M4.972.36M0%+$020.53
Deep Track Capital Lp$104.12M2.751.3M+30.47%+$24.32M0.48
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.